On the Record · Centene

Centene acquisitions, on the record

The businesses Centene bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Magellan Health, Inc. Word for word“Total consideration for the acquisition was $2.5 billion, consisting of $2.4 billion in cash and $60 million related to the fair value of replacement equity awards associated with pre-combination service.” 10-K for 2022	acquisition	—	$2.5 billion
PANTHERx Rare Word for word“We completed the divestiture of PANTHERx in July 2022 for $1.4 billion and recognized a gain of $490 million, or $382 million after-tax.” 10-K for 2022	divestiture	July 2022	$1.4 billion
Magellan Rx Word for word“In December 2022, we completed the divestiture of Magellan Rx for $1.3 billion and recognized a gain of $269 million, or $99 million after-tax.” 10-K for 2022	divestiture	In December 2022	$1.3 billion
Spanish and Central European businesses Word for word“Additionally, as part of our review of strategic alternatives for our international portfolio, in November 2022 we divested our ownership stakes in our Spanish and Central European businesses and as a result recorded an impairment charge of $163 million, or $140 million after-tax.” 10-K for 2022	divestiture	November 2022	—
Magellan Specialty Health, Centurion, and HealthSmart Word for word“In January 2023, we completed the divestitures of Magellan Specialty Health, Centurion, our prison healthcare business, and HealthSmart, our third party health plan administration business.” 10-K for 2022	divestiture	In January 2023	—
USMM Word for word“In December 2021, we sold a majority stake in USMM, our physician home health business.” 10-K for 2022	divestiture	In December 2021	—
Circle Health Word for word“In July 2021, we acquired the remaining interest in our equity method investment in Circle Health, one of the U.K.'s largest independent operators of hospitals.” 10-K for 2022	acquisition	In July 2021	—
Operose Health Group Word for word“In December 2023, we completed the divestiture of Operose Health Group (Operose Health) and recognized an impairment of $140 million, or $128 million after-tax.” 10-K for 2023	divestiture	December 2023	—
Circle Health Group Word for word“The divestiture was completed in January 2024.” 10-K for 2023	divestiture	January 2024	—
Apixio Word for word“In June 2023, we completed the divestiture of our majority stake in Apixio and recognized a gain of $93 million, or $67 million after-tax.” 10-K for 2023	divestiture	June 2023	—
Magellan Specialty Health Word for word“In January 2023, we sold Magellan Specialty Health for $646 million in cash and stock, including an estimated working capital adjustment, and recognized a gain of $79 million, or $63 million after-tax.” 10-K for 2023	divestiture	January 2023	$646 million in cash and stock
Centurion and HealthSmart Word for word“In January 2023, we also completed the divestitures of Centurion and HealthSmart and recorded impairments of $259 million ($181 million after-tax) and $36 million ($27 million after-tax), respectively, in 2022.” 10-K for 2023	divestiture	January 2023	—
Operose Health Group (Operose Health) Word for word“In December 2023, we completed the divestiture of Operose Health Group (Operose Health) and recognized an impairment of $140 million, or $128 million after-tax.” 10-K for 2024	divestiture	In December 2023	—
Circle Health Group (Circle Health) Word for word“In January 2024, we completed the divestiture of Circle Health Group (Circle Health) for $931 million.” 10-K for 2024	divestiture	In January 2024	$931 million
Collaborative Health Systems (CHS) Word for word“In October 2024, we completed the divestiture of Collaborative Health Systems (CHS) and recognized a pre-tax gain of $17 million, or $13 million after-tax.” 10-K for 2024	divestiture	In October 2024	—
remaining Magellan Health businesses Word for word“In December 2025, we signed a definitive agreement to divest the remaining Magellan Health businesses.” 10-K for 2025	agreed divestiture	December 2025	—

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)	Goodwill from acquisitions
2016-12-31	—	$3.87 billion
2017-12-31	$50 million	$37 million
2018-12-31	$2.06 billion	$2.27 billion
2019-12-31	$36 million	$108 million
2020-12-31	$4.05 billion	$11.87 billion
2021-12-31	$534 million	$1.17 billion
2022-12-31	$1.46 billion	$1.08 billion
2023-12-31	$0	—
2024-12-31	$0	—

Deal filings since 2016

2025-03-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-06-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-01-04 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2021-12-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-08-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-08-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-03-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-02-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-01-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-10-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-02-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-01-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-01-23 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2019-12-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-11-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-09-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-05-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-03-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-07-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-07-02 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2018-05-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-12-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-09-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-11-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-06-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-03-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-03-24 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2016-02-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Centene’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023, 10-K for 2022) and the financial data it files with the SEC, as of 2026-02-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.